The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitor
In this video Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on results from a subset of patients in the BRUIN study (NCT03740529) who stopped prior covalent Bruton’s tyrosine kinase (BTK) inhibitor therapy because of intolerance. In this cohort, the majority of patients were able to go onto the non-covalent BTK inhibitor pirtobrutinib and respond. Moreover, those that discontinued pirtobrutinib did not do so because of the same adverse event as when they stopped the covalent BTKi, suggesting the toxicities are different. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy; Miltenyi Biotec: Consultancy, Research Funding; Lilly Oncology: Consultancy, Honoraria; Epizyme: Consultancy; Bristol Myers Squibb: Consultancy; Incyte Corporation: Consultancy, Honoraria, Speakers Bureau; TG therapeutics: Consultancy; Kite Pharma: Consultancy.
